On July 30, KRA
embarked on a countrywide public participation exercise targeting manufacturers of non-alcoholic drinks and the public on the implementation of the second Phase of Excisable Goods Management System (EGMS).
"Defaulters took advantage of this vacuum to lodge cases at the Tax Appeals Tribunal and we could only wait," says KRA
commissioner-general James Mburu, who took over in June.Mr Rotich who was dropped from Cabinet in the wake of Kimwarer and Arror tml" target="_blankdam scandals only gazetted members of the independent tribunal on April 2019, some 12 months after the previous team exited leaving only the chairman in office.
, which operates primarily in the RV and industrial markets, is a manufacturer of wire harnesses and associated assemblies for RVs, commercial vehicles, lawn care equipment, marine products, the defense industry, and automotive aftermarket products.
Established in 1995, Kenya Revenue Authority (KRA
) has the responsibility of collecting revenue on behalf of the Kenyan government to finance service delivery to an estimated population of +44 million, increasing by one million per annum.
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has revealed new results from a global survey demonstrating that 66% of patients with metastatic colorectal cancer (mCRC) are now tested for KRAS
to determine if they could benefit from a personalized therapy, such as ErbituxEeA (cetuximab).
or BRAF mutations are present in nearly half of CRC tumors.
However, recent results of first-line therapy of cetuximab in combination with chemotherapy have shown effectiveness only in KRAS
wt patients [1,23,24].
More patients with wild-type KRAS
tumors responded to cemximab (Erbitux) plus the FOLFIRI (leucovorin, fluorouracil, and irinotecan) chemotherapy regimen (59%) than to FOLFIRI alone (43%), reported Dr.
Now, Elicio Therapeutics, a next generation immuno-oncology company, is presenting significant preclinical data from a novel lymph-node targeted vaccine targeting the seven KRAS
mutations that drive 99% of all KRAS-driven cancers, estimated to be 25% of all human solid tumors.
In a clinical diagnostic setting, observation of unexpected coexisting mutations, such as KRAS
and EGFR mutations in a lung cancer specimen, raises concern for laboratory errors.